An additional feature of clinically relevant MER-targeted therapy is a potential increased efficacy of standard chemotherapeutics, which have previously been shown to interact synergistically with shRNA-mediated MER inhibition in NSCLC, and with small molecule-mediated MER inhibition in ALL [13, 25]. This evidence concerns the gene MERTK and acute lymphoblastic leukemia.